Aisha I Abdullah PhD,  —

The DuchenneXchange online social platform has launched a mobile and desktop app for the Duchenne muscular dystrophy (DMD) community, to encourage discussion and to share news, diagnosis and treatment resources, and clinical trial information. The goal for the new app is to make the…

The final patient has finished the first, six-month portion of the pivotal VISION-DMD Phase 2b clinical trial, assessing the anti-inflammatory steroid therapy vamorolone in boys with Duchenne muscular dystrophy (DMD). Top-line data from this part of…

Edgewise Therapeutics has received $95 million in funding to advance the clinical development of its experimental therapy EDG-5506, designed to improve physical functioning in people with Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD).

Sarepta Therapeutics’ investigational treatment SRP-5051 enhanced cell penetration, exon skipping, and dystrophin levels at a lower dose than its Exondys 51 (eteplirsen) therapy in a Phase 2 clinical trial in patients with Duchenne muscular dystrophy (DMD).

Ultragenyx Pharmaceutical and Solid Biosciences announced a strategic collaboration to develop and commercialize new gene therapies for Duchenne muscular dystrophy (DMD). The collaboration will combine Solid’s gene therapy construct for DMD and Ultragenyx’s cell…

The 11th annual Ryan’s Day fundraiser, organized by rapper Wheelz to raise awareness of Duchenne muscular dystrophy and help find a cure, will be live-streamed on Facebook on Oct. 24 at 1 p.m. (ET). Official Ryan’s Day 11 Poster…